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Abstract
Background: Genome-wide RNA interference screening study revealed that loss of expression of insulin-like
growth factor binding protein 7 (IGFBP7) is a critical step in development of a malignant melanoma (MM), and this
secreted protein plays a central role in apoptosis of MM. In this study we constructed pcDNA3.1-IGFBP7 to obtain
high expression of IGBPF7 and to inhibit the growth of MM in C57BL/6J mice.
Methods: pcDNA3.1-IGFBP7 was transfected into B16-F10 cell, the expression of IGFBP7 was detected by RT-PCR
and western blot. The proliferations and apoptosis rates of transfected and control cells were measured by CCK8
and FCM, respectively. The tumorigenicity and tumor growth in both pcDNA3.1-IGFBP7 group and control groups
were studied in C57BL/6J mice model. IGFBP7, caspase-3, and VEGF expressions in tumor tissue were measured by
immunohistochemistry. Apoptosis of tumors were detected by TUNEL.
Results: We demonstrated this plasmid inhibited proliferation of B16-F10 melanoma cells efficiently in vivo,
exploiting the high expression of IGFBP7. More importantly, in-vivo transfection of pcDNA3.1-IGFBP7 inhibited MM
growth in C57BL/6J mice. The inhibition of MM growth was proved owing to apoptosis and reduced expression of
VEGF induced by pcDNA3.1-IGFBP7.
Conclusions: These results suggest a potential new clinical strategy for MM gene treatment.
Background
MM is responsible for 80% of skin cancer deaths, and to
date its incidence has been increasing. Although devel-
opment of surgical, chemotherapeutic and radiothera-
peutic treatment keeps ongoing, the 5-year survival rate
of late stage MM patients is only 10-20% [1-4]. There-
fore, a new effective therapy for MM is highly desired.
In the previous studies, we demonstrated that the synth-
esis of vascular endothelial growth factor (VEGF) and
growth of MM in xenograf models [3] were significantly
inhibited by using small-interfering RNA (siRNA),
which makes us believe that the modulation of aberrant
signaling pathways in MM cell will probably provide
more effective and potential nontoxic therapy for MM.
However, this approach still has its shortcomings, in
that VEGF is one of the downstream target genes
of insulin-like growth factor (IGF), which is important
in promoting tumor angiogenesis [5-8]. Although
pU-VEGF-siRNA directly inhibited MM cell prolifera-
tion by reducing VEGF expression, it could not induce
valid apoptosis.
Recently, immunohistochemical analysis of human
skin, nevi, and melanoma samples implicates loss of
IGFBP7 expression as a critical step in melanoma carci-
nogenicity [9]. Thus, the relationship between IGF axis
and carcinogenesis has become one of the hottest spots.
The IGF system is composed of IGFs, IGF receptors,
and Insulin-like growth factor-binding proteins
(IGFBPs). IGFBP7 belongs to the IGFBP superfamilies.
It is also known as IGFBP-related protein 1 (IGFBP-rP1)
or Mac25. It is a member of soluble protein family that
b i n d sI G F sw i t hl o wa f f i n i t y ,a n di se x p r e s s e di naw i d e
range of tissues [10,11]. In-vitro studies demonstrated
that IGFBP7 induced the apoptosis of many cancer cells
[12,13], e.g., breast and prostate cancer cells, and plays a
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any medium, provided the original work is properly cited.potential tumor suppressor role against colorectal carci-
nogenesis. Moreover, Wajapeyee, [9] et al showed that
recombinant IGFBP7 (rIGFBP7) induced apoptosis in
melanoma cell lines, efficiently. These exciting data sug-
gested that IGFBP7 may be an efficacious anticancer
agent, since experiments have provided evidences that
IGFBPs have both IGF-dependent and IGF-independent
antitumoral actions [13,14].
Recent data also demonstrated that a prostatic carci-
noma cell line stably transfected with IGFBP7 cDNA
showed poor tumorigenicity both in vitro and in vivo
[10]. Meanwhile, in our previous study, we found that
IGFBP7 expression was low in B16-F10 cells. However,
it is still unclear whether IGFBP7 cDNA inhibits prolif-
eration of B16-F10 cells in vitro or B16-F10 MM growth
in vivo. Therefore, in the present study, we constructed
the pcDNA3.1-IGFBP7 plasmid as an antitumor agent
to investigate whether it is effective in treating mice
bearing B16-F10 melanoma tumor.
Methods
Plasmid construction
The pcDNA3.1-IGFBP7 expression plasmid was con-
structed. IGFBP7 gene (GenBank ID: 29817 No.
AK156315.1) was amplified by RT-PCR from mRNA
of splenocytes derived from C57BL/6J mice (IGFBP7 fw:
5’GAAGATCTATGGAGCGGCCGTCGCT-3’,I G F B P 7
rev: 5’-CGGAATTCTTTATAGCTCGGCACCTTCA-
CCT-3’). IGFBP7 cDNA was purified by Shanghai Biolo-
gical Engineering Company. The eukaryotic vector
expressing eGFP and IGFBP7 was termed as pcDNA3.1-
IGFBP7, and pcDNA3.1-CONTROL only expressed
eGFP. The inserted sequences were verified by DNA
sequencing, and digested by restriction endonuclease
(EcoRI, and Bgl II enzyme).
Tumor cells and in vitro transfection with pcDNA3.1-
IGFBP7
B16-F10 cells were purchased from the Institute of Cell
Biology (Shanghai institute for biological sciences). Cells
were seeded in six-well plates (2 × 10
5 cells per well),
cultured overnight at 37°C in 5% CO2,a n dg r o w nt o
60% confluence prior to transfection. Transfection with
pcDNA3.1-IGFBP7 was performed by Effectene Trans-
fection Reagent (QIAGEN Companies) according to the
manufacturer’s instructions. Cells transfected with
pcDNA3.1-CONTROL and those without any transfec-
tion served as controls. The experimental and two con-
trol groups were termed pcDNA3.1-IGFBP7, pcDNA3.1-
CONTROL and B16-F10 cells, respectively. All experi-
ments were preformed in triplicate and repeated at least
twice.
RT-PCR and gelelectrophoresis
Total RNA from 1 × 10
6 cultured cells was extracted using
the TRIZOL reagent (Invitrogen, San Diego, U.S.A.). Then
RNA was reversely transcribed and synthesized to cDNA
using Reverse transcriptase (Rever TraAce-a-TM,
TOYOBO, JAPAN). Primer sequences for IGFBP7 (fw:
5’-GTAAGGAGGACGCTGGAGAGT-3’,r e v :5 ’-CTGG-
CTGTAATAAAGTGTTAGTGG-3’)a n db-actin (fw:
5’-CCGTGAAAAGTGACCCAG-3’ rev: 5’-TAGCCAC-
GCTCGGTCAGG-3’). PCR and gelelectrophoresis condi-
tions were described as previous [3]. The expected size of
fragment of IGFBP7 and b-actin was 255 bp, 136 bp,
respectively.
Analysis of Cell Viability
Cell viability was determined by the Cell Counting Kit-8
(Dojindo Laboratories, Kumamoto, Japan) and measured
by microplate reader scanning at 450 nm as previously
described elsewhere [15].
Quantification of cell apoptosis by flow cytometry
B16-F10 cells were washed by PBS and collected after
digestion by 0.25% trypsin, cell suspension was added
dropwise to PBS while gently vortexed, then centrifuged
at 1000 rpm at 4°C for 10 min. After resuspension of
the cells in labeling buffer, 10 μl Annexin VFITC was
added and then incubated in the dark. Following 150 μL
of propidium iodide (PI) was added, the cells were incu-
bated for 2 h at room temperature. Then cell apoptosis
was measured by flow cytometry [16,17].
Mice
Thirty-six six-week-old female Wild-type C57BL/6J mice
weighing 18-25 g were treated in accordance with the
guidelines of the National Institutes of Health for the
humane treatment of animals, and all animal protocols
were approved by Huazhong University of Science and
Technology’s animal care and use committee. Mice were
anesthetized with urethane (1.9 g/kg sc; 12.5 mg urethane/
ml 0.9% saline; Sigma Chemical, St. Louis, MO), and their
temperature was maintained at 37°C[18]. 1 × 10
4 B16-F10
cells were injected subcutaneously in the lower backs of
mice, where MM emerged after 1 week. Tumor volume
(v) was calculated as follow, v = L × I
2 ×0 . 5
2,w h e r eLa n d
I represent the maximum and minimum tumor diameter
measured weekly. All the mice were divided into three
groups randomly (n = 12 each group), termed pcDNA3.1-
IGFBP7, pcDNA3.1-CONTROL and B16-F10 cells groups
respectively. Then Invivofectamine reagent-plasmid duplex
complexes 200 μl (Reagent for in vivo plasmid delivery,
Invitrogen, U.S.A), containing pcDNA3.1-IGFBP7 (1 μg),
or pcDNA3.1-CONTROL (1 μg), DMEM 200 μlw e r e
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delivery efficiency was evaluated by GFP fluorescence and
RT-PCR. After 3 weeks the mice were killed (with permis-
sion of the Animal Protection Association of Tongji Medi-
cal College). Tumors were cryosectioned or fixed in 10%
buffered formalin and embedded in paraffin detected by
immunohistochemistry.
Western blot analysis
IGFBP7 expression changes within mouse xenografts
were checked by western blotting as described pre-
viously [19], the antibodies to IGFBP7 and b-actin were
purchased from (R&D systems U.S.A.).
Detection of IGFBP7, caspase-3, VEGF by
immunohistochemistry or laser scanning confocal
microscopy
Detection is based on the formation of the Avidin-Biotin
Complex (ABC) with primary antibodies that reacted
with tissue antigens. Primary antibodies were listed as
follows: IGFBP7(1:25 R&D systems U.S.A MAB21201),
caspase-3(1:20 R&D systems U.S.A MAB835), VEGF
(1:20 Santa Cruz Biotechnology, sc-7269). Coverslips
containing pcDNA3.1-IGFBP7, pcDNA3.1-CONTROL
tumor section were mounted onto glass slides and
observed with a Zeiss 510 confocal microscope. Green
fluorescent protein and TRITC-labeled IGFBP7 were
viewed through the GFP, and tetramethyl rhodamine
isothiocyanate (TRITC) fluorescence channel, respec-
tively. Appropriate positive and negative controls were
included. The expression of caspase-3 and VEGF visuali-
zation is based on enzymatic conversion of a chromo-
genic substrate (AEC), (CTS018 R&D systems U.S.A).
No significant difference in intensity of immunohisto-
chemical staining was designated as negative (0), positive
(1), strong positive (2) and the percentage of positive
cells was scored as less than 5% (0), 5%~25% (1), 26%
~50% (2), 51%~75% (3) or over 75% (4) of cells stained
[20]. Values in the parentheses were multiplied together
to the scores for IGFBP7, caspase-3, VEGF expression.
Detection of tumor apoptosis
Tumor apoptosis was detected using terminal deoxynu-
cleotidyl transferase-mediated deoxyuridine triphosphate
nick end labelling (TUNEL, Catalog # 11684809910,
ROCHE Germany) according to the supplier’si n s t r u c -
tions, and apoptosis index (AI) was used to evaluate cell
apoptosis.
Statistics
The statistical analysis was performed using SPSS 13.0
software (SPSS, Chicago, IL, U.S.A.). Statistical compari-
sons of mean values were performed using Student’s
t-test and Kruskal-Wallis Test, the correlations was
analyzed by Spearman’s rho correlation analysis. All
P-values were determined from two-sided tests. A signif-
icance criterion of P < 0.05 was used in these studies.
Results
Identification of pcDNA3.1-IGFBP7 plasmid
The sequence analysis of constructed pcDNA3.1-
IGFBP7 by a DNA sequencer showed the same
sequence of eukaryotic IGFBP7 mRNA as designed.
Meanwhile, recombinant pcDNA3.1-IGFBP7 plasmid
was confirmed by restriction enzyme analysis, as shown
in additional files 1, Figure S1. These results indicated
that the pcDNA3.1-IGFBP7 vector was constructed suc-
cessfully. Then pcDNA3.1-IGFBP7 and pcDNA3.1-
CONTROL were transfected into cells successfully,
termed pcDNA3.1-IGFBP7 cells and pcDNA3.1-CON-
TROL cells, respectively with transfection rate being
about 60%, as shown in additional files 1, Figure S2.
Effect of pcDNA3.1-IGFBP7 plasmid on IGFBP7 expression
It was found that the IGFBP7 mRNA levels in pcDNA3.1-
IGFBP7-transfected B16-F10 cells were increased by about
4-fold, 8-fold, 7-fold, 6-fold on days 1, 3, 6 and 12, respec-
tively, compared with the control group. But no change
of IGFBP7 expression in pcDNA3.1-CONTROL groups
(P > 0.05) was found, suggesting that pcDNA3.1-IGFBP7
vector specifically promotes expression of IGFBP7 without
effects on b-actin mRNA,, as shown in additional files 2,
Figure S1. Meanwhile, the expression of IGFBP7 was
detected by western blot. The western blot showed that
pcDNA3.1-IGFBP7 increased the expression of IGFBP7.
Results are consistent with previous determined by
RT-PCR. According to these results detected by RT-PCR
and western blot, the IGFBP7 expressed in the pcDNA3.1-
IGFBP7 group were significantly higher in the pcDNA3.1-
CONTROL and B16-F10 cells groups (p < 0.03), as shown
in additional files 2, Figure S2.
pcDNA3.1-IGFBP7 suppresses B16-F10 cells growth in
vitro
The proliferation of pcDNA3.1-IGFBP7-transfected cells
was significantly suppressed compared with control cells
(P < 0.01). The highest suppression effect of pcDNA3.1-
IGFBP7 was found at 48 h post-transfection, and no signif-
icant difference in proliferation between pcDNA3.1-CON-
TROL and untransfected cells was observed (P >0 . 0 5 ) ,
indicating that transfection of pcDNA3.1-IGFBP7 blocks
the proliferation of B16-F10 cells by increasing IGFBP7
synthesis and secretion, as shown in additional files 2,
F i g u r eS 3 .T oe v a l u a t ea p o ptosis-induced effect of
pcDNA3.1-IGFBP7 in melanoma cells, B16-F10 cells at 48
h post-transfection was monitored by FCM. The apoptosis
rate in pcDNA3.1-IGFBP7 group (24.6%) was significantly
higher than that in control groups (P < 0.01). However, no
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(6.1%) and B16-F10 groups (5.3%). Our finding mentioned
above indicates that the long-term IGFBP7 expression
possibly establishes a desirable basis for the therapeutic
effect in vitro.
Effect of pcDNA3.1-IGFBP7 on IGFBP7 expression and
growth of MM homeograft in vivo
To evaluate the therapeutic potential of pcDNA3.1-
IGFBP7 on B16-F10 MM homeograft in vivo,w ep e r -
formed intratumoral injection of pcDNA3.1-IGFBP7 to
study the effect on carcinogenesis. The results showed
that pcDNA3.1-IGFBP7 inhibited tumor growth, at the
time of killing, the volumes of MM in B16-F10 cell group
and pcDNA3.1-CONTROL group were 587 ± 35 mm
3
and 566 ± 34 mm
3, respectively, being about 6-fold
increase over the starting volume; whereas the volume of
B16-F10 tumors injected with pcDNA3.1-IGFBP7 were
256 ± 25 mm
3, with the volume increase being only 2.8-
fold. The delay in tumor growth was statistically significant
(P < 0.001). To evaluate the expression of IGFBP7 in
tumor homeograft, the proteins were determined by wes-
tern blotting. IGFBP7 expression in the pcDNA3.1-
IGFBP7 group was significantly higher than in pcDNA3.1-
CONTROL and B16-F10 cells groups (p < 0.01), whereas
there was no significant difference in IGFBP7, expression
was found between pcDNA3.1-CONTROL and B16-F10
cells groups (p > 0.05). Transfection of pcDNA3.1-IGFBP7
in vivo not only inhibited MM growth in C57BL/6J mice,
but also prolonged C57BL/6J mice survival bearing B16-
F10 melanoma tumor.
Effect of pcDNA3.1-IGFBP7 on IGFBP7, caspase-3, VEGF
and apoptosis expression in vivo
To investigate the effect of pcDNA3.1-IGFBP7 on IGFBP7,
caspase-3, VEGF expression, and MM apoptosis in vivo,
we performed fluorescent immunohistochemistry and
cytometry. As shown in Fig. 1. IGFBP7 and caspase-3,
VEGF were mainly expressed in the cytoplasm of tumor
cells. IGFBP7 was determined by fluorescent immunohis-
tochemistry, positive staining of TRITC labeled IGFBP7
protein is red and localized in the cytoplasm, while GFP
protein expressed by plasmids is green. The expression of
caspase-3 and VEGF visualization is based on AEC stain-
ing. The results are consistent with our hypothesis, as
show in Fig. 1. A-F that IGFBP7 and caspase-3 expression
in the pcDNA3.1-IGFBP7 group is significantly higher in
the pcDNA3.1-CONTROL and B16-F10 cells groups
(IGFBP7 P < 0.002, caspase-3 p < 0.004), but VEGF
expression in the pcDNA3.1-IGFBP7 group is significantly
lower in the pcDNA3.1-CONTROL and B16-F10 cells
groups (P < 0.006) (Fig. 1. G-I) respectively, and no signifi-
cant difference in IGFBP7 and caspase-3. VEGF expression
is found between the pcDNA3.1-CONTROL and B16-F10
cells groups (P > 0.05). According to these results deter-
mined by immunohistochemistry, there were significantly
more apoptotic cells in the pcDNA3.1-IGFBP7 group than
in the pcDNA3.1-CONTROL and B16-F10 cells groups
(p < 0.031). As shown in Fig. 1. J-L, morphological charac-
ters of apoptotic cells are cell shrinkage, deformation, and
loss of contact with neighbouring cells. Fig. 1. J shows
more apoptotic cells in the pcDNA3.1-IGFBP7 group than
in the pcDNA3.1-CONTROL (Fig. 1. K), and B16-F10
cells groups (Fig. 1. L), which contained almost the
same numbers of apoptotic cells. The expression of
IGFBP7 is positively correlated with caspase-3, and cell
apoptosis rate (rs = 0.704, rs = 0.806 respectively, p < 0.01).
However there is negative correlation between IGFBP7
and VEGF rs = -0.564, p < 0.01). These results suggested
that pcDNA3.1-IGFBP7 inhibited the proliferation of MM
cells by up-regulating IGFBP7 and caspase-3 expression
Figure 1 Detection of IGFBP7, caspase-3, VEGF, and apoptosis
expressed in homeograft tumors sections with original
magnification × 100 in A-F, and ×400 in G-L. A shows
significantly higher IGFBP7 expression in pcDNA3.1-IGFBP7. B
demonstrates the successful transfection of pcDNA3.1 plasmid.
C shows the physiological expression of IGFBP7 in melanoma (red
color, as blue arrows indicate). D-F shows the effect of pcDNA3.1-
IGFBP7 on caspase-3 expression in the cytoplasm of tumor sections,
with strong expression in pcDNA3.1-IGFBP7 group seen in D, while
weak expression in the pcDNA3.1-CONTROL and B16-F10 cell
groups seen in E, F. G-I shows the expression of VEGF in vivo, with
negative expression in most of cells in the pcDNA3.1-IGFBP7 group
seen in G, while strong expression in the cytoplasm of pcDNA3.1-
CONTROL and B16-F10 cell groups (red arrow represented) showed
in H, I. J-L shows tumor apoptosis in vivo, with few apoptotic cells
in pcDNA3.1-CONTROL (K) and B16-F10 cell groups (L), while
increased apoptosis in the B16-F10 tissue in mice treated with
pcDNA3.1-IGFBP7 (J) (red arrow shows deep blue cells).
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slowing down of MM growth.
As to show the exactitude of our experiment design,
we used pcDNA3.1-IGFBP7 simultaneously expressed
GFP and IGFBP7 rather than pcDNA3.1 plasmid con-
taining only IGFBP7 gene. That was because, if we used
pcDNA3.1 plasmid only containing IGFBP7 gene, we
could not estimate the transfection efficiency in-vivo
experiments, and moreover, we could not discriminate
whether high level of IGFBP7 expression in xenograft
sections dued to plasmid transfection or physiological
IGFBP7 synthesis of melanoma. Well, pcDNA3.1-
IGFBP7 simultaneously expressed GFP and IGFBP7
could solve both of the problems, as shown in additional
files 3, Figure S2. We evaluated apoptosis-induced effect
in melanoma cells of pcDNA3.1 only containing IGFBP7
gene, and in those of pcDNA3.1-IGFBP7 simultaneously
expressed GFP and IGFBP7, finding out that insersion
of GFP would not affect the expression of IGFBP7, as
shown in additional files 3, Figure S1.
Discussion
It has been confirmed that transfection with anti-tumor
plasmids is more specific, more efficient, and longer last-
ing for anti-tumor therapy than recombinant protein.
Transfection of anti-tumor plasmids may have some
advantages over the application of rIGFBP7, namely the
less danger of immunological rejection and the low cost
of synthesis and purification [3]. In addition, MM cells
transfected with eukaryotic expression plasmids could
have stable and effective expression of IGFBP7 gene. Our
research demonstrated that pcDNA3.1-IGFBP7 vector
promotes expression of IGFBP7 specifically and have a
long-lasting effect. However, it is conflicting to our
hypothesis that IGFBP7 expression should ascensus, but
i tw a sa t t e n u a t eo v e rt i m e .T h ep o s s i b l ee x p l a n a t i o nf o r
this phenomenon was attributed to the high performance
of PCMV promoter contained in pcDNA3.1-IGFBP7,
which would exhaust and be toxic to tumor cells since it
ad infinitum synthesized IGFBP7. Meanwhile augmenta-
tion of IGFBP7 in cell supernatant would induce apopto-
sis of part of tumor cells and therefore, the synthesis of
IGFBP7 also decreases with reduction of tumor cells.
To determine therapeutic potential of pcDNA3.1-
IGFBP7 in vitro, we analyzed cells viability and apoptosis
rates by the Cell Counting Kit-8 and FCM. Our results are
consistent with the research of Sprenger [13], which indi-
cated that the growth of a tumorigenic SV40 prostate cell
line, M12, was suppressed by transfecting the IGFBP-rP1
cDNA. Also, prostatic carcinoma cells were stably trans-
fected with IGFBP7 cDNA and showed poor tumorigeni-
city [21]. Moreover, IGFBP7 which acts through
autocrine/paracrine pathways to inhibit BRAF-MEK-ERK
signaling and induce apoptosis [9], but it is contradictory
to some researcher’s findings, as they indicated that
IGFBP7 was highly overexpressed in glioma tissues, med-
iateing glioma cell growth, and migration [22]. In addition,
the expression pattern of IGFBP7 varies with tumor types.
Both up-regulated expression [23] and down-regulated
expression [24,25] of IGFBP7 is observed in different types
of cancer. In our previous study, we found that IGFBP7
expression was low in B16-F10 cells. Vladislava [26] also
indicated that unlike human melanomas, the murine mela-
noma cell lines (B16-F10) did not have activating muta-
tions in the Braf oncogene at exon 11 or 15, however,
there were distinct patterns of mutation in the ras gene.
RAS proteins are membrane-bounded small G proteins,
and RAF, MEK, and ERK are cytosolic protein kinases that
form a tiered protein kinase cascade downstream of RAS,
whereas ARAF and CRAF are not mutated because their
regulation is fundamentally different from that of BRAF.
As a consequence, RAS is mutated in melanoma, the cells
(B16-F10) switch their signaling from BRAF to CRAF [27],
then IGFBP7 expression is decreased, enabling the cells to
escape from senescence and resulting in uncontrolled pro-
liferation. Accordingly, RAS-CRAF-MEK-ERK pathways
contribute to the development of murine melanoma.
Transfection of pcDNA3.1-IGFBP7 into B16-F10 cells,
upgraded the expression of IGFBP7, which inhibits CRAF-
MEK-ERK signaling through an autocrine/paracrine path-
way, thereby restraining proliferation and activates apopto-
sis. Together, these results suggest that IGFBP7 plays
different roles in different t u m o ro rh o s te n v i r o n m e n t s .
Therefore, we need to evaluate the therapeutic potential of
pcDNA3.1-IGFBP7 on B16-F10 in vivo.
Although the apoptosis-inducing effect of pcDNA3.1-
IGFBP7 in cultured cells was shown for in vitro applica-
tions, its therapeutic applications in vivo represent an alto-
gether more daunting challenge. To elevate transfection
efficiency, we employed Invivofectamine (a new in vivo
plasmid delivery reagent) to carry pcDNA3.1-IGFBP7
transfected into tumors tissue. Fortunately, our data
clearly showed that intratumoral injection of the Invivofec-
tamine pcDNA3.1-IGFBP7 complex was able to slow
down the growth of B16-F10 MM homograft, and its
transfection efficiency was about 70%. Most importantly, it
had a lasting effect on tumor development, being effective
for at least 20 days, because stable expression of IGFBP7
by using pcDNA3.1-IGFBP7. We focused on the therapeu-
tic mechanisms of the Invivofectamine pcDNA3.1-IGFBP7
complex in B16-F10 MM homograft. The antitumor
research of IGFBP has provided evidence that IGFBPs may
have both IGF-dependent and independent actions.
We hypothesized that IGFBP7 can inhibit MM gowth by
IGF-dependent way [14], and reduce VEGF expression
through preventing IGF-Ibinding to its receptors. In addi-
tion, IGFBP7 induces MM apoptosis through a novel
IGF-independent pathway. To confirm the presumption,
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apoptosis in tumor homograft tissues. The results of the
immunohistochemistry and TUNEL showed that, IGFBP7
and caspase-3 expression in pcDNA3.1-IGFBP7 group are
significantly higher than in pcDNA3.1-CONTROL and
B16-F10 cells groups, but VEGF expression in the
pcDNA3.1-IGFBP7 group were significantly lower than
both in control groups, and no significant difference in
IGFBP7 and caspase-3, VEGFe x p r e s s i o nw e r ef o u n d
between the pcDNA3.1-CONTROL and B16-F10 cells
groups. According those results determined by immuno-
histochemistry, there were significantly more apoptotic
cells in the pcDNA3.1-IGFBP7 group than in control
groups. This was considered possibly to relate to IGFBP7
promote apoptosis effectiveness. However, our finding
contrasted with the results of Adachi [28] et al, who found
that high expression of IGFBP7 in invasive tumor cells
was associated with poor prognosis. This discrepancy may
be due to the difference in the immunohistochemical scor-
ing [20,29]. We used the composite score to evaluate the
expression of IGFBP7, which seems to be one of the most
promising and accurate scoring systems currently defined.
Futhermore, we demonstrated that the expression
of IGFBP7 is positive correlation with caspase-3, and cell
apoptosis rate. In addition, there is negative correlation
between IGFBP7 and VEGF. Those results suggested that
pcDNA3.1-IGFBP7 can up-regulate IGFBP7, caspase-3
expression, and down-regulate VEGF expression in vivo to
inhibit the proliferation of MM cells, which resulted in
slowing down of MM growth, as shown in additional files
4. Angiogenesis is essential for tumor development, and
the increasing evidences show that IGF-I plays a crucial
role in tumor growth by up-regulating the VEGF expres-
sion and neovascularisation [30]. A recent study indicated
that IGFBP7 might exhibit angiogenesis-modulating prop-
erties, reducing VEGF expression by regulating IGF avail-
ability in body fluids and tumor tissues and modulating
combination of IGF-I to its receptors [30,31]. Moreover
the reduction of VEGF-induced tube formation by
IGFBP7 could be mainly mediated by inhibition of MAP
kinase cascade through c-Raf, and BRAF-MEK-ERK sig-
nalling [32], Although our research implied IGFBP7 blocks
VEGF-induced angiogenesis and VEGF expression by
interfering with IGF-I, its role in tumor angiogenesis
r e m a i n sp o o r l yu n d e r s t o o d .T h em e c h a n i s m sb yw h i c h
IGFBP7 induced apoptosis and inhibit neovascularization
should be further explored.
Conclusion
Our data show that increasing IGFBP7 expression by
using the pcDNA3.1-IGFBP7 plasmid suppresses MM
growth, induces apoptosis and reduces VEGF in vitro
and in vivo. Intratumoral injection of pcDNA3.1-
IGFBP7 holds promise as a clinical gene therapy
approach for MM, which provide a framework for
further studies of its broader applicability to a range of
human tumors. However, there are several insufficien-
cies on this therapeutics. Firstly, it would be difficult to
make uniform distribution of pcDNA3.1-IGFBP7 in
tumor tissue by intratumoral injection of invivofectamin,
and a transferrin-polyethylenimine (Tf-PEI) delivery sys-
tem (our previous studies) needs to be used in the
further study. Secondly, there are no suitable MM cell
lines available that express high level of IGFBP7 to
prove the specificity of anti-tumor effect of pcDNA3.1-
IGFBP7. Moreover, many biological roles of pcDNA3.1-
IGFBP7 remain to be elucidated.
Additional file 1: pcDNA3.1-IGFBP7 plasmid checked by restriction
enzyme analysis, and transfection with Effectene authenticated by
immunofluorescence. Restriction enzyme analysis of pcDNA3.1-IGFBP7
plasmid by EcoR I and Bgl II manifested that the obtained plasmid was
the objective one with predicted length. Plasmid transfection with
Effectene was successful, authenticated by immunofluorescence.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-9966-29-
13-S1.PDF]
Additional file 2: Effect of pcDNA3.1-IGFBP7 plasmid on IGFBP7
expression in vitro. Higher concentration of pcDNA3.1-IGFBP7 plasmid led
to higher IGFBP7 mRNA and protein expression in B16-F10 melanoma cells,
detected by RT-PCR and western blot. pcDNA3.1-IGFBP7 transfection led to
reduction of B16-F10 cells viability, determined by the Cell Counting Kit-8.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-9966-29-
13-S2.PDF]
Additional file 3: Effect of different plasmids on tumor cell apoptosis
rate detected by flow cytometry and laser scanning confocal
microscopy. Apoptosis rate detected by flow cytometry of B16 melanoma
resulted in an obvious increase in pcDNA3.1-IGFBP7 group than those in
pcDNA3.1-CONTROL and B16 groups, consistent with laser confocal display
of tumor sections of the three groups, suggested significant effects of in-
vitro and in-vivo pcDNA3.1-IGFBP7 transfection on B16 apoptosis.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-9966-29-
13-S3.PDF]
Additional file 4: In-vivo anti-tumor effect of pcDNA3.1-IGFBP7
plasmid. Survival curves and tumor volumes showed different effects of the
three groups. pcDNA3.1-IGFBP7 group has a significantly higher survival rate
and smaller tumor size, compared to pcDNA3.1-CONTROL and B16-F10
groups.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1756-9966-29-
13-S4.PDF]
Abbreviations
IGFBP7: insulin-like growth factor binding protein 7; MM: malignant
melanoma; VEGF: vascular endothelial growth factor; TUNEL: terminal
deoxynucleotidyl transferase-mediated deoxyuridinetriphosphate nick end
labelling.
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